title: Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase.
abstract: This paper aimed to investigate the effect of lumbrokinase on the anticoagulation and fibrinolysis in treating cerebral infarction. Lumbrokinase was used in patients with cerebral infarction. Patients were randomly divided into treatment group (n = 31) and control group (n = 20). Single blind method was used in this investigation. The Chinese stroke score was used to evaluate the results of treatment before and after administration of lumbrokinase. Kaolin partial thromboplastin time (KPTT), prothrombin time (PT), fibrinogen content, vWF content were analyzed, and tissue plasminogen activator (t-PA) activity, plasminogen activator inhibitor (PAI) activity, D-dimer level were assayed. In both groups, the stroke score decreased after administration, but in the treatment group, it was more obvious. In the treatment group, KPTT was prolonged, t-PA activity and D-dimer level increased, while the content of fibrinogen decreased significantly. There were no significant changes of PT and PAI activity in both groups. It is concluded that lumbrokinase is beneficial to the treatment of cerebral infarction. The effect of lumbrokinase is related to the inhibition of intrinsic coagulation pathway and the activation of fibrinolysis via an increase of t-PA activity.
authors.affiliation: Department of Neurology, Zhongshan Hospital, Shanghai Medical University, China.
authors.forename: L
authors.initials: L
authors.lastname: Jin
authors.forename: H
authors.initials: H
authors.lastname: Jin
authors.forename: G
authors.initials: G
authors.lastname: Zhang
authors.forename: G
authors.initials: G
authors.lastname: Xu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D002544:Cerebral Infarction / Q000097:blood / Q000188:drug therapy*; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D016037:Single-Blind Method; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000032:analysis*; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; C036309:fibrin fragment D; D014841:von Willebrand Factor; D005340:Fibrinogen; D010450:Endopeptidases; D010959:Tissue Plasminogen Activator; C083421:lumbrokinase